NASDAQ:BWAY

BrainsWay - BWAY Stock Forecast, Price & News

$2.00

-0.03 (-1.48%)

(As of 02/7/2023 03:40 PM ET)

Add

Compare

Today's Range: $1.98
▼
$2.01
50-Day Range: $1.73
▼
$2.47
52-Week Range: $1.64
▼
$9.18

Volume: 32,012 shs
Average Volume: 79,396 shs
Market Capitalization: $33.08 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $9.19

Institutional Ownership

BrainsWay MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 359.4% Upside
$9.19 Price Target
Short Interest: Healthy
0.39% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.27
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.41) to ($0.40) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.45 out of 5 stars

Medical Sector

157th out of 1,029 stocks

Surgical & Medical Instruments Industry

15th out of 105 stocks

3.5

Analyst's Opinion

Consensus Rating
BrainsWay has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $9.19, BrainsWay has a forecasted upside of 359.4% from its current price of $2.00.
Amount of Analyst Coverage
BrainsWay has only been the subject of 3 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.39% of the outstanding shares of BrainsWay have been sold short.
Short Interest Ratio / Days to Cover
BrainsWay has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in BrainsWay has recently decreased by 32.45%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
BrainsWay does not currently pay a dividend.
Dividend Growth
BrainsWay does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for BWAY.

2.4

News and Social Media Coverage

News Sentiment
BrainsWay has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.48 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for BrainsWay this week, compared to 2 articles on an average week.
Search Interest
1 people have searched for BWAY on MarketBeat in the last 30 days.
MarketBeat Follows
2 people have added BrainsWay to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, BrainsWay insiders have not sold or bought any company stock.
Percentage Held by Insiders
19.00% of the stock of BrainsWay is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
47.94% of the stock of BrainsWay is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for BrainsWay are expected to grow in the coming year, from ($0.41) to ($0.40) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of BrainsWay is -6.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of BrainsWay is -6.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
BrainsWay has a P/B Ratio of 0.57. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About BrainsWay (NASDAQ:BWAY) Stock

Brainsway Ltd. is a commercial stage medical device company, which focuses on the development and sale of non-invasive neuromodulation products using the proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) technology for the treatment of major depressive disorder (MDD) and obsessive-compulsive disorder (OCD). The Deep TMS uses magnetic pulses to stimulate neurons and consequently modulates the physiological activity of the brain. The company was founded by Avner Hagai, Yiftach Roth, Abraham Zangen, and David Zacut on November 7, 2006 and is headquartered in Jerusalem, Israel.

Receive BWAY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BrainsWay and its competitors with MarketBeat's FREE daily newsletter.

BWAY Stock News Headlines

February 2, 2023 | americanbankingnews.com

BrainsWay's (BWAY) Buy Rating Reaffirmed at HC Wainwright

January 31, 2023 | finance.yahoo.com

Publication Analyzes Clinical Efficacy of Deep TMS™ in Treating Different Brain Regions Associated with Major Depressive Disorder

February 7, 2023 | Investing Trends (Ad)

GRAPHITE: "Essential for America's National Defense"

Did you know each EV battery contains up to 220 pounds of graphite and China controls more than 90% of the world's graphite trade? But now that the U.S. has classified it as "essential for America's National Defense"... one little-known company could become America's ONLY fully integrated graphite provider.

January 11, 2023 | finance.yahoo.com

BrainsWay Announces Extended Private Insurance Coverage in Washington State for the Treatment of OCD and Depression Utilizing Deep TMS™

January 10, 2023 | finance.yahoo.com

Neuronetics Settles Unfair Competition Related Litigation Against BrainsWay

January 10, 2023 | finance.yahoo.com

BrainsWay Resolves Neuronetics Litigation

December 13, 2022 | finance.yahoo.com

BrainsWay Reports Open Market Stock Purchase by Board Member Yossi Ben Shalom

November 28, 2022 | finance.yahoo.com

BrainsWay Reports Open Market Stock Purchases by Two Board Members

February 7, 2023 | Investing Trends (Ad)

GRAPHITE: "Essential for America's National Defense"

November 16, 2022 | finance.yahoo.com

BrainsWay Reports Third Quarter 2022 Financial Results and Operational Highlights

November 3, 2022 | finance.yahoo.com

BrainsWay Announces Private Insurance Coverage from Premera Blue Cross for the Treatment of OCD Utilizing Deep TMS™

November 2, 2022 | finance.yahoo.com

BrainsWay to Report Third Quarter Financial Results on November 16, 2022

November 1, 2022 | finance.yahoo.com

BrainsWay Appoints Dr. Colleen A. Hanlon as Vice President of Medical Affairs

October 12, 2022 | globenewswire.com

Rise in Mental Health Issues to push Depression Treatment Market to surpass US$ 16.8 Bn by 2032 | Future Market Insights, Inc. - GlobeNewswire

October 12, 2022 | finance.yahoo.com

BrainsWay Launches Social Media Sweepstakes in Observance of Depression Awareness Month - Yahoo Finance

October 12, 2022 | globenewswire.com

BrainsWay Launches Social Media Sweepstakes in Observance of Depression Awareness Month - GlobeNewswire

October 12, 2022 | finance.yahoo.com

BrainsWay Launches Social Media Sweepstakes in Observance of Depression Awareness Month

October 11, 2022 | globenewswire.com

BrainsWay and NOCD Launch Collaboration to Increase Awareness of OCD Treatments - GlobeNewswire

October 11, 2022 | finance.yahoo.com

BrainsWay and NOCD Launch Collaboration to Increase Awareness of OCD Treatments

October 5, 2022 | nytimes.com

What to See on Broadway in October

September 20, 2022 | globenewswire.com

BrainsWay CEO Christopher von Jako Named Honorary Chair of NAMIWalks Silicon Valley - GlobeNewswire

September 20, 2022 | finance.yahoo.com

BrainsWay CEO Christopher von Jako Named Honorary Chair of NAMIWalks Silicon Valley

September 14, 2022 | globenewswire.com

BrainsWay Announces Significant Private Insurance Coverage from Cigna Corporation for the Treatment of OCD Utilizing Deep TMS - GlobeNewswire

September 14, 2022 | finance.yahoo.com

BrainsWay Announces Significant Private Insurance Coverage from Cigna Corporation for the Treatment of OCD Utilizing Deep TMS™

September 2, 2022 | finance.yahoo.com

BrainsWay to Present at the H.C. Wainwright Annual Global Investment Conference - Yahoo Finance

August 31, 2022 | uk.investing.com

Why Nikola Dropped Over 9%; Here Are 66 Biggest Movers From Yesterday By Benzinga - Investing.com UK

August 31, 2022 | nasdaq.com

BrainsWay Climbs 6% On FDA Clearing Its Deep TMS H7 Coil To Treat Depression

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive BWAY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BrainsWay and its competitors with MarketBeat's FREE daily newsletter.

BWAY Company Calendar

Last Earnings: 11/16/2022
Today: 2/07/2023
Next Earnings (Estimated): 3/08/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Surgical & medical instruments
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:BWAY
CUSIP: N/A
CIK: 1505065
Web: www.brainsway.com
Phone: (722) 582-4030
Fax: N/A
Employees: 100
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $9.19
High Stock Price Forecast: $15.00
Low Stock Price Forecast: $3.75
Forecasted Upside/Downside: +359.4%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.32)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-6,460,000.00
Net Margins: -36.57%
Pretax Margin: -36.95%
Return on Equity: -20.09%
Return on Assets: -15.02%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 6.85
Quick Ratio: 6.48

Sales & Book Value

Annual Sales: $29.66 million
Price / Sales: 1.12
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.48 per share
Price / Book: 0.57

Miscellaneous

Outstanding Shares: 16,540,000
Free Float: 13,396,000
Market Cap: $33.08 million
Optionable: Not Optionable
Beta: 0.97

Key Executives

Christopher R. von Jako
President & Chief Executive Officer

Hadar Levy
Chief Operating Officer & Senior Vice President

Richard Scott Areglado
Chief Financial Officer & Senior Vice President

Yiftach Roth
Chief Scientific Officer

Moria Ankri
Vice President-Research & Development

Key Competitors

View All Competitors

Insiders & Institutions

View All Institutional Transactions

BWAY Stock - Frequently Asked Questions

Should I buy or sell BrainsWay stock right now?: 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BrainsWay in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BWAY shares.
View BWAY analyst ratings or view top-rated stocks.
What is BrainsWay's stock price forecast for 2023?: 4 analysts have issued 12-month price objectives for BrainsWay's stock. Their BWAY share price forecasts range from $3.75 to $15.00. On average, they anticipate the company's share price to reach $9.19 in the next twelve months. This suggests a possible upside of 353.1% from the stock's current price.
View analysts price targets for BWAY or view top-rated stocks among Wall Street analysts.
How have BWAY shares performed in 2023?: BrainsWay's stock was trading at $2.47 at the start of the year. Since then, BWAY stock has decreased by 17.9% and is now trading at $2.0275.
View the best growth stocks for 2023 here.
When is BrainsWay's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 8th 2023.
View our BWAY earnings forecast.
How were BrainsWay's earnings last quarter?: BrainsWay Ltd. (NASDAQ:BWAY) released its quarterly earnings results on Wednesday, November, 16th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.07) by $0.08. The company earned $5.17 million during the quarter, compared to analyst estimates of $8.52 million. BrainsWay had a negative net margin of 36.57% and a negative trailing twelve-month return on equity of 20.09%.
What other stocks do shareholders of BrainsWay own?: Based on aggregate information from My MarketBeat watchlists, some companies that other BrainsWay investors own include AbbVie (ABBV), Advanced Micro Devices (AMD), Enterprise Products Partners (EPD), Pfizer (PFE), Neuronetics (STIM), Boingo Wireless (WIFI), Ampio Pharmaceuticals (AMPE), Eastman Chemical (EMN), Enbridge (ENB) and Energy Transfer (ET).

When did BrainsWay IPO?: (BWAY) raised $30 million in an IPO on Wednesday, April 17th 2019. The company issued 2,500,000 shares at $11.94 per share. Cantor acted as the underwriter for the IPO.
What is BrainsWay's stock symbol?: BrainsWay trades on the NASDAQ under the ticker symbol "BWAY."
Who are BrainsWay's major shareholders?: BrainsWay's stock is owned by many different retail and institutional investors. Top institutional investors include Taylor Frigon Capital Management LLC (1.15%).
How do I buy shares of BrainsWay?: Shares of BWAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is BrainsWay's stock price today?: One share of BWAY stock can currently be purchased for approximately $2.03.
How much money does BrainsWay make?: BrainsWay (NASDAQ:BWAY) has a market capitalization of $33.53 million and generates $29.66 million in revenue each year. The company earns $-6,460,000.00 in net income (profit) each year or ($0.32) on an earnings per share basis.
How can I contact BrainsWay?: BrainsWay's mailing address is 19 HARTUM STREET BYNET BUILDING 3RD FL Har HaHotzvim, Jerusalem L3, 9777518. The official website for the company is www.brainsway.com. The company can be reached via phone at (722) 582-4030 or via email at hadarl@brainsway.com.

This page (NASDAQ:BWAY) was last updated on 2/7/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

BrainsWay - BWAY Stock Forecast, Price & News

BrainsWay MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About BrainsWay (NASDAQ:BWAY) Stock

BWAY Stock News Headlines

BWAY Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

BWAY Stock - Frequently Asked Questions

Overall MarketRank^™